QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:OCGN

Ocugen (OCGN) Stock Price, News & Analysis

$1.64
-0.14 (-7.87%)
(As of 05:22 PM ET)
Today's Range
$1.57
$1.76
50-Day Range
$0.50
$1.83
52-Week Range
$0.35
$2.11
Volume
9.06 million shs
Average Volume
7.83 million shs
Market Capitalization
$420.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.33

Ocugen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
166.3% Upside
$4.33 Price Target
Short Interest
Bearish
13.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Ocugen in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

Medical Sector

805th out of 938 stocks

Biological Products, Except Diagnostic Industry

134th out of 154 stocks

OCGN stock logo

About Ocugen Stock (NASDAQ:OCGN)

Ocugen, Inc. is a biopharmaceutical company founded in 2013, dedicated to developing and commercializing innovative therapies to treat rare eye diseases and other disorders. With a mission to improve patients' lives through cutting-edge research and development, Ocugen is focused on creating transformative treatments that address unmet medical needs.

Headquartered in Malvern, Pennsylvania, Ocugen operates with a global mindset. The company leverages strategic partnerships and collaborations to advance its research and deliver its products worldwide. Ocugen's commitment to innovation and patient-centric solutions has earned it a reputation as a trusted leader in the biotechnology industry.

Ocugen's primary focus is developing gene therapies and biologics for treating rare eye diseases such as inherited retinal disorders and dry eye disease. By harnessing the potential of genetic medicine, Ocugen aims to provide patients with groundbreaking treatments that can significantly improve their quality of life. The company is also actively researching and developing vaccines, including a COVID-19 vaccine candidate.

The target market for Ocugen's products and services includes patients globally suffering from rare eye diseases. By addressing these underserved markets, Ocugen is poised to significantly impact the lives of patients who previously had limited treatment options.

Key customers of Ocugen include healthcare providers, hospitals, clinics, and patients. Ocugen's focus on building solid relationships with key stakeholders has allowed the company to gain traction and establish itself as a trusted partner in the healthcare ecosystem.

In terms of recent achievements, Ocugen has made remarkable progress. The company's most notable milestone was the advancement of its COVID-19 vaccine candidate, COVAXIN, in collaboration with Bharat Biotech. COVAXIN gained emergency use authorization in several countries, including India, and demonstrated promising efficacy against emerging virus variants. This achievement solidified Ocugen's position as a key player in the fight against the COVID-19 virus.

The management team at Ocugen comprises accomplished individuals with diverse backgrounds and extensive industry experience. Dr. Shankar Musunuri, the Chairman, Chief Executive Officer, and Co-Founder, is a seasoned entrepreneur with a successful track record in the biotechnology sector. His leadership has been instrumental in guiding the company's strategic vision and driving its growth. 

Regarding financial performance, Ocugen has not yet achieved profitability, and the stock has continued to drop because the FDA continues to place hold statuses on its developing vaccine and drugs. However, Ocugen's debt levels remain manageable, enabling the company to invest in research and development initiatives without compromising its long-term financial stability. 

Analyzing the company's valuation metrics is crucial in understanding its market positioning. Compared to industry peers, Ocugen's price-to-earnings ratio demonstrates the market's positive sentiment toward the company's growth prospects. Several factors influence the company's valuation. Firstly, the successful advancement of Ocugen's product pipeline, particularly its gene therapies and biologics, contributes to investor optimism. These innovative treatments could revolutionize the field of ophthalmology and address unmet medical needs.

Furthermore, the company's collaboration with Bharat Biotech on the development of COVAXIN has garnered significant attention. The emergency use authorization and promising efficacy data of COVAXIN have positioned Ocugen as a critical player in the global fight against COVID-19 and generated investor confidence in the company's ability to deliver effective vaccines.

However, it's important to note that external factors beyond the company's control can also influence stock prices, such as market conditions, investor sentiment toward the broader biotechnology industry, or geopolitical events. Therefore, thorough analysis and market performance monitoring are essential to understanding Ocugen's stock dynamics.

The biotechnology sector is highly competitive and constantly evolving. Ocugen operates within a niche market of rare eye diseases and genetic therapies, facing both established pharmaceutical companies and emerging biotechnology startups as competitors. Ocugen must maintain a competitive edge by leveraging its innovative technologies, strong research capabilities, and strategic collaborations.

Regulatory and political factors also play a significant role in the biotechnology industry. Changes in regulations or government policies related to drug development, intellectual property rights, or pricing can impact the industry landscape. Ocugen must stay abreast of these developments to ensure compliance and mitigate potential risks.

Looking ahead, Ocugen has several growth opportunities on the horizon. The successful commercialization of its pipeline products has the potential to drive substantial revenue growth. Additionally, the company can explore expansion into new markets and indications, leveraging its expertise in genetic medicine to target other rare diseases beyond ophthalmology.

Furthermore, strategic acquisitions or partnerships with other biotechnology companies can enhance Ocugen's product portfolio and expand its reach. Ocugen can capitalize on its strengths and propel its long-term success by actively pursuing these growth opportunities.

The biotechnology industry has risks and challenges. Market volatility, clinical trial failures, regulatory hurdles, and pricing pressures are among the key risks that Ocugen faces. The company must employ robust risk management strategies to mitigate these challenges effectively.

Ocugen's risk management approach should include diversification of its product pipeline, a thorough evaluation of clinical trial protocols, and proactive engagement with regulatory authorities to navigate the complex regulatory landscape. Furthermore, a comprehensive understanding of the competitive environment and monitoring market trends are crucial to adapt to changing market dynamics.

OCGN Stock Price History

OCGN Stock News Headlines

What's Going On With Ocugen Stock?
Ocugen (NASDAQ:OCGN) Reaches New 12-Month High at $1.98
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Why Is Ocugen (OCGN) Stock Up 20% Today?
3 Stocks Under $5 Ready to Outpace the Market
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Ocugen Names Qamar Chief Medical Officer
OCGN Apr 2024 1.500 call
Ocugen to Present at Investing in Cures Summit
Ocugen Clinical Showcase Webcast Now Available
Ocugen, Inc. (OCGN)
5 Hot Penny Stock On the Move
See More Headlines
Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/22/2023
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OCGN
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.33
High Stock Price Target
$7.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+143.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-81,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.38 per share

Miscellaneous

Free Float
247,576,000
Market Cap
$456.57 million
Optionable
Optionable
Beta
3.44
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Shankar Musunuri M.B.A. (Age 60)
    Ph.D., Co-Founder, CEO & Chairman
    Comp: $1.2M
  • Dr. Uday B. Kompella Ph.D. (Age 57)
    Co-founder & Independent Director
    Comp: $56.72k
  • Mr. Michael Breininger CPA (Age 42)
    M.B.A., Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller
  • Dr. Arun Upadhyay Ph.D. (Age 41)
    Chief Scientific Officer and Head of Research & Development
  • John Kouch J.D.
    General Counsel
  • Ms. Tiffany J. Hamilton M.B.A.
    Head of Corporate Communications
  • Mr. Michael Shine M.B.A.
    Senior Vice President of Commercial
  • Ms. Jyothy Pillai M.S.
    Head of Regulatory & Quality

OCGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocugen stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCGN shares.
View OCGN analyst ratings
or view top-rated stocks.

What is Ocugen's stock price target for 2024?

3 Wall Street analysts have issued 1-year price objectives for Ocugen's stock. Their OCGN share price targets range from $2.00 to $7.00. On average, they anticipate the company's share price to reach $4.33 in the next year. This suggests a possible upside of 166.3% from the stock's current price.
View analysts price targets for OCGN
or view top-rated stocks among Wall Street analysts.

How have OCGN shares performed in 2024?

Ocugen's stock was trading at $0.5750 at the beginning of 2024. Since then, OCGN stock has increased by 183.0% and is now trading at $1.6273.
View the best growth stocks for 2024 here
.

When is Ocugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our OCGN earnings forecast
.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.03.

What ETF holds Ocugen's stock?

Invesco Nasdaq Future Gen 200 ETF holds 76,301 shares of OCGN stock, representing 0.63% of its portfolio.

What other stocks do shareholders of Ocugen own?
Who are Ocugen's major shareholders?

Ocugen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.69%), Vanguard Group Inc. (4.69%), Luminus Management LLC (0.63%), Northern Trust Corp (0.20%), Price T Rowe Associates Inc. MD (0.07%) and Price T Rowe Associates Inc. MD (0.07%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends
.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners